Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors

Zoledronic Acid Enhances Vδ2 T-Lymphocyte Antitumor Response to Human Glioma Cell Lines

(2017) E. Cimini et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation

(2015) Larisa Pereboeva et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Structural and functional features of central nervous system lymphatic vessels

(2015) Antoine Louveau et al.   NATURE

Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling

(2015) Emeline Brocard et al.   Oncotarget

Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion

(2015) Eva Rietkötter et al.   Oncotarget

The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human Vγ9Vδ2 T Cells

(2014) Andrew Sandstrom et al.   IMMUNITY

Macrophage Depletion by Free Bisphosphonates and Zoledronate-Loaded Red Blood Cells

(2014) Raffaella Sabatino et al.   PLoS One

A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy

(2014) Dong-Sup Chung et al.   Journal of Immunology Research

Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme

(2013) Der-Yang Cho et al.   CELL TRANSPLANTATION

Repeated Systemic Administrations of Both Aminobisphosphonates and Human V 9V 2 T Cells Efficiently Control Tumor Development In Vivo

(2013) T. Santolaria et al.   JOURNAL OF IMMUNOLOGY

Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma

(2013) Tsutomu Nakazawa et al.   JOURNAL OF NEURO-ONCOLOGY

Chondroitin Sulfate Proteoglycans Potently Inhibit Invasion and Serve as a Central Organizer of the Brain Tumor Microenvironment

(2013) D. J. Silver et al.   JOURNAL OF NEUROSCIENCE

Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial

(2013) Manfred Westphal et al.   LANCET ONCOLOGY

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human    T-cell subset

(2012) C. Harly et al.   BLOOD

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy

(2012) Valérie Dutoit et al.   BRAIN

What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

(2012) Jean-Jacques Fournié et al.   Cellular & Molecular Immunology

Primary brain tumours in adults

(2012) Damien Ricard et al.   LANCET

Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma

(2011) Hirohito Kobayashi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cellular immunotherapy for high-grade glioma

(2011) Kevin KH Chow et al.   Immunotherapy

Biochemical and molecular mechanisms of action of bisphosphonates

(2010) Michael J. Rogers et al.   BONE

Overview of Cellular Immunotherapy for Patients with Glioblastoma

(2010) Elodie Vauleon et al.   Clinical & Developmental Immunology

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Risks and benefits of bisphosphonates

(2008) R E Coleman   BRITISH JOURNAL OF CANCER

Biodistribution and Plasma Protein Binding of Zoledronic Acid

(2008) H. M. Weiss et al.   DRUG METABOLISM AND DISPOSITION

Presence of pluripotent CD133+ cells correlates with malignancy of gliomas

(2008) Niklas Thon et al.   MOLECULAR AND CELLULAR NEUROSCIENCE